Approximately 2 million people in the U.S. sustain a traumatic brain injury (TBI) each year with over 250,000 hospitalizations and 50,000 deaths. There has been a significant rise in interest in diagnosing mild concussions, particularly in the sports world. While imaging has been the gold standard, these procedures are costly and not always available. There is great potential in using serum-based biomarkers. However, there are many challenges in creating and implementing new laboratory tests for TBI, ranging from scientific discovery, regulatory issues, commercialization, and reimbursement. Biomarkers for Traumatic Brain Injury provides a comprehensive overview of selection and implementation of serum-based biomarkers for traumatic brain injury. The book covers economic analysis for implementing TBI biomarkers into clinical practice. It also discusses the analytical tools needed to implement TBI biomarkers including the specifications for testing instruments and interpretative software. Neurologists, emergency department physicians, intensivists, and clinical laboratorians can use this book to become familiar with the issues and process regarding TBI biomarkers. Offers strategies for the selection and implementation of traumatic brain injury biomarkers Discusses the importance of autoantibodies and post translational modifications for TBICovers analytical tools needed to implement TBI biomarkers including the specifications for testing instruments and interpretative software INDICE: 1. Scope of the problem Pathophysiology of TBI 2. Blood brain barrier pathophysiology 3. Apoptosis 4. Autoimmune response 5. Post translational modifications in TBI TBI biomarkers in medical practice 6. Correlation and complementation to neural imaging techniques 7. Diagnostic need in the emergency department 8. Diagnostic need for the intensive care unit 9. Outpatient risk assessment following TBI 10. Physiologic TBI biomonitoring 11. TBI therapeutics Classical and novel TBI Biomarkers 12. Classical TBI biomarkers 13. Low molecular weight metabolomics markers 14. Autoantibodies for risk stratification 15. Novel biomarkers including citrillinated G-fab, neurogranin, and brain derived neurotropic factor Analytical and clinical laboratory testing consideration 16. Strategies for biobanking 17. Analytical performance goals 18. Sensitivity immunoassay testing platforms 19. High sensitivity mass spectrometry 20. Alternate sample matricies for biomarker testing (e.g., CSF, oral fluids) 21. Algorithms and interpretative software 22. The regulatory environment for TBI biomarkers 23. Economic analysis and justification for TBI biomarkers
- ISBN: 978-0-12-816346-7
- Editorial: Academic Press
- Encuadernacion: Rústica
- Páginas: 250
- Fecha Publicación: 01/02/2020
- Nº Volúmenes: 1
- Idioma: Inglés